AU2019297498A1 - Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody - Google Patents
Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody Download PDFInfo
- Publication number
- AU2019297498A1 AU2019297498A1 AU2019297498A AU2019297498A AU2019297498A1 AU 2019297498 A1 AU2019297498 A1 AU 2019297498A1 AU 2019297498 A AU2019297498 A AU 2019297498A AU 2019297498 A AU2019297498 A AU 2019297498A AU 2019297498 A1 AU2019297498 A1 AU 2019297498A1
- Authority
- AU
- Australia
- Prior art keywords
- freeze
- pellets
- antibody
- solution
- fxia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F26—DRYING
- F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
- F26B5/00—Drying solid materials or objects by processes not involving the application of heat
- F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
- F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
- F26B5/065—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing the product to be freeze-dried being sprayed, dispersed or pulverised
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Mechanical Engineering (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Glanulating (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Drying Of Solid Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2018068250 | 2018-07-05 | ||
EPPCT/EP2018/068250 | 2018-07-05 | ||
PCT/EP2019/068071 WO2020008022A1 (en) | 2018-07-05 | 2019-07-05 | METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2019297498A1 true AU2019297498A1 (en) | 2021-01-21 |
Family
ID=67139764
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019298656A Pending AU2019298656A1 (en) | 2018-07-05 | 2019-07-05 | Novel stable high-concentration formulation for anti-FXIa antibodies |
AU2019297498A Abandoned AU2019297498A1 (en) | 2018-07-05 | 2019-07-05 | Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (FXIa) antibody |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2019298656A Pending AU2019298656A1 (en) | 2018-07-05 | 2019-07-05 | Novel stable high-concentration formulation for anti-FXIa antibodies |
Country Status (16)
Country | Link |
---|---|
US (2) | US20210290534A1 (pt) |
EP (2) | EP3817723A1 (pt) |
JP (2) | JP2021529801A (pt) |
KR (2) | KR20210029221A (pt) |
CN (2) | CN112367975A (pt) |
AR (1) | AR115713A1 (pt) |
AU (2) | AU2019298656A1 (pt) |
BR (2) | BR112020026789A2 (pt) |
CA (2) | CA3105256A1 (pt) |
IL (2) | IL279868A (pt) |
MX (2) | MX2021000037A (pt) |
PE (2) | PE20210779A1 (pt) |
SA (1) | SA521420957B1 (pt) |
SG (2) | SG11202100028PA (pt) |
TW (1) | TW202034898A (pt) |
WO (2) | WO2020008035A1 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3105256A1 (en) * | 2018-07-05 | 2020-01-09 | Bayer Aktiengesellschaft | Novel stable high-concentration formulation for anti-fxia antibodies |
WO2022122993A1 (en) * | 2020-12-11 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Formulation for multi-purpose application |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0859841B1 (en) | 1995-08-18 | 2002-06-19 | MorphoSys AG | Protein/(poly)peptide libraries |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
US7836606B2 (en) * | 2004-07-23 | 2010-11-23 | Bayer Technology Services Gmbh | Sterile freezing, drying, storing, assaying and filling process |
US8383114B2 (en) | 2007-09-27 | 2013-02-26 | Amgen Inc. | Pharmaceutical formulations |
EP2578975A1 (en) | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Rotary drum freeze-dryer |
EP2578974A1 (en) * | 2011-10-05 | 2013-04-10 | Sanofi Pasteur Sa | Process line for the production of freeze-dried particles |
ES2698950T3 (es) * | 2012-05-10 | 2019-02-06 | Bayer Pharma AG | Anticuerpos capaces de unirse al Factor XI de coagulación y/o a su forma activada, Factor XIa, y usos de los mismos |
US9592297B2 (en) * | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
BR112015008186A2 (pt) | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
CN107206070B (zh) | 2014-10-23 | 2022-01-18 | 美国安进公司 | 降低药物制剂的粘度 |
EP3167877A1 (en) * | 2015-11-12 | 2017-05-17 | Bayer Pharma Aktiengesellschaft | Method for the production of freeze-dried pellets comprising factor viii |
US20190060241A1 (en) * | 2016-04-13 | 2019-02-28 | Medimmune, Llc | Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents |
ES2770674T3 (es) * | 2016-06-10 | 2020-07-02 | Octapharma Ag | Composición de inmunoglobulinas de alta concentración para aplicaciones farmacéuticas |
KR102616666B1 (ko) * | 2016-12-23 | 2023-12-27 | 노파르티스 아게 | 인자 xi 항체 및 사용 방법 |
CA3105256A1 (en) * | 2018-07-05 | 2020-01-09 | Bayer Aktiengesellschaft | Novel stable high-concentration formulation for anti-fxia antibodies |
-
2019
- 2019-07-05 CA CA3105256A patent/CA3105256A1/en active Pending
- 2019-07-05 CA CA3105261A patent/CA3105261A1/en not_active Abandoned
- 2019-07-05 BR BR112020026789-9A patent/BR112020026789A2/pt unknown
- 2019-07-05 EP EP19735338.6A patent/EP3817723A1/en active Pending
- 2019-07-05 SG SG11202100028PA patent/SG11202100028PA/en unknown
- 2019-07-05 CN CN201980044750.XA patent/CN112367975A/zh active Pending
- 2019-07-05 KR KR1020217003292A patent/KR20210029221A/ko unknown
- 2019-07-05 TW TW108123732A patent/TW202034898A/zh unknown
- 2019-07-05 US US17/257,827 patent/US20210290534A1/en not_active Abandoned
- 2019-07-05 WO PCT/EP2019/068106 patent/WO2020008035A1/en active Application Filing
- 2019-07-05 PE PE2020002228A patent/PE20210779A1/es unknown
- 2019-07-05 MX MX2021000037A patent/MX2021000037A/es unknown
- 2019-07-05 BR BR112020026492-0A patent/BR112020026492A2/pt not_active Application Discontinuation
- 2019-07-05 PE PE2020002238A patent/PE20210462A1/es unknown
- 2019-07-05 CN CN201980050959.7A patent/CN112543627A/zh active Pending
- 2019-07-05 US US17/257,828 patent/US20210292434A1/en active Pending
- 2019-07-05 EP EP19735335.2A patent/EP3817727A1/en not_active Withdrawn
- 2019-07-05 JP JP2021500070A patent/JP2021529801A/ja active Pending
- 2019-07-05 AR ARP190101919A patent/AR115713A1/es unknown
- 2019-07-05 WO PCT/EP2019/068071 patent/WO2020008022A1/en active Application Filing
- 2019-07-05 AU AU2019298656A patent/AU2019298656A1/en active Pending
- 2019-07-05 AU AU2019297498A patent/AU2019297498A1/en not_active Abandoned
- 2019-07-05 KR KR1020217003293A patent/KR20210028673A/ko active Search and Examination
- 2019-07-05 MX MX2021000028A patent/MX2021000028A/es unknown
- 2019-07-05 SG SG11202100046UA patent/SG11202100046UA/en unknown
- 2019-07-05 JP JP2021500069A patent/JP2021529800A/ja active Pending
-
2020
- 2020-12-30 IL IL279868A patent/IL279868A/en unknown
- 2020-12-30 IL IL279865A patent/IL279865A/en unknown
-
2021
- 2021-01-03 SA SA521420957A patent/SA521420957B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
PE20210779A1 (es) | 2021-04-21 |
SG11202100046UA (en) | 2021-02-25 |
BR112020026492A2 (pt) | 2021-04-06 |
AR115713A1 (es) | 2021-02-17 |
PE20210462A1 (es) | 2021-03-08 |
CA3105256A1 (en) | 2020-01-09 |
MX2021000037A (es) | 2021-03-25 |
BR112020026789A2 (pt) | 2021-03-30 |
KR20210029221A (ko) | 2021-03-15 |
WO2020008022A1 (en) | 2020-01-09 |
IL279865A (en) | 2021-03-01 |
AU2019298656A1 (en) | 2021-01-28 |
KR20210028673A (ko) | 2021-03-12 |
IL279868A (en) | 2021-03-01 |
SA521420957B1 (ar) | 2023-12-14 |
CA3105261A1 (en) | 2020-01-09 |
EP3817727A1 (en) | 2021-05-12 |
CN112543627A (zh) | 2021-03-23 |
SG11202100028PA (en) | 2021-01-28 |
TW202034898A (zh) | 2020-10-01 |
MX2021000028A (es) | 2021-03-09 |
WO2020008035A1 (en) | 2020-01-09 |
CN112367975A (zh) | 2021-02-12 |
US20210292434A1 (en) | 2021-09-23 |
EP3817723A1 (en) | 2021-05-12 |
JP2021529801A (ja) | 2021-11-04 |
JP2021529800A (ja) | 2021-11-04 |
US20210290534A1 (en) | 2021-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7382232B2 (ja) | 抗lag3抗体の製剤および抗lag3抗体と抗pd-1抗体との共製剤 | |
CN106999591A (zh) | 一种抗pd‑1抗体制剂及其在医药上的应用 | |
US20110070225A1 (en) | Beta antibody parenteral formulation | |
TWI592426B (zh) | 胞漿素原活化素抑制劑-1(pai-1)之抗體及其用途 | |
US20210290534A1 (en) | METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY | |
CN112142845A (zh) | 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 | |
US20150307606A1 (en) | Lyophilized spherical pellets of anti-il-23 antibodies | |
CN112513096B (zh) | 改进的促凝血抗体 | |
US11713922B2 (en) | Target residual moisture content for lyophilized drug product | |
Schneider et al. | Shelf-life extension of Fc-fused single chain fragment variable antibodies by lyophilization | |
CN115996704A (zh) | 抗体制剂稀释剂 | |
CA3118178A1 (en) | Tissue plasminogen activator antibodies and method of use thereof | |
Joerg et al. | Introduction into novel constructs | |
TW202417038A (zh) | 高度濃縮的抗體組成物 | |
KR20190136428A (ko) | 분말상 단백질 조성물 및 이의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |